Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 7/20 | 0.44 |
| ▸ | PRF1 | P14222 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12174319 | 1.00 | BACE1 (0.44) | BACE1PRF1PGRHPGDSCTSD | |
| SCHEMBL8212244 | 1.00 | BACE1 (0.44) | BACE1PRF1PGRHPGDSCTSD | |
| SCHEMBL13054199 | 1.00 | BACE1 (0.44) | BACE1PRF1PGRHPGDSCTSD | |
| SCHEMBL7541121 | 0.93 | BACE1 (0.45) | BACE1PRF1PGRHPGDSCTSD | |
| SCHEMBL7604106 | 0.93 | BACE1 (0.45) | BACE1PRF1PGRHPGDSCTSD | |
| SCHEMBL7545931 | 0.93 | BACE1 (0.45) | BACE1PRF1PGRHPGDSCTSD | |
| SCHEMBL7576383 | 0.92 | BACE1 (0.44) | BACE1PRF1PGRHPGDSCTSD | |
| SCHEMBL7554034 | 0.92 | BACE1 (0.44) | BACE1PRF1PGRHPGDSCTSD | |
| SCHEMBL13055092 | 0.92 | BACE1 (0.44) | BACE1PRF1PGRHPGDSCTSD | |
| SCHEMBL8202524 | 0.91 | BACE1 (0.45) | BACE1PRF1PGRHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183252-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | BACE1 8/4885PRF1 3012/4885PGR 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.